Cipher Pharmaceuticals Inc
PHE
Company Profile
Business description
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company is building its business through product acquisitions, out-licensing, and in-licensing arrangements. Its products include Dermatology Products, Hospital Acute Care Products, specialty medicines, and Out-Licensed Products, among others. The company's geographical operational areas include Canada and the United States.
Contact
5750 Explorer Drive
Suite 404
MississaugaONL4W 0A9
CANT: +1 905 602-5840
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
43
Stocks News & Analysis
stocks
CSL’s latest result suggests the worst may be over
Relief replaces disappointment but can growth return?
stocks
ASX listed pharma boosted by weight loss drugs
GLP-1 momentum drives earnings for narrow moat share.
stocks
Nvidia earns upgrade as AI buildouts accelerate
Demand for AI infrastructure shows no signs of slowing.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,289.10 | 24.00 | 0.26% |
| CAC 40 | 8,401.18 | 81.31 | 0.98% |
| DAX 40 | 26,569.99 | 202.75 | 0.77% |
| Dow JONES (US) | 53,559.99 | 9.45 | -0.02% |
| FTSE 100 | 10,824.26 | 31.72 | 0.29% |
| HKSE | 25,388.87 | 195.92 | -0.77% |
| NASDAQ | 26,402.42 | 138.93 | -0.52% |
| Nikkei 225 | 65,361.60 | 1,043.96 | -1.57% |
| NZX 50 Index | 13,869.89 | 101.71 | 0.74% |
| S&P 500 | 7,711.76 | 19.23 | -0.25% |
| S&P/ASX 200 | 9,095.10 | 29.50 | 0.33% |
| SSE Composite Index | 3,941.59 | 10.59 | -0.27% |